Stocks and Investing
Stocks and Investing
Wed, April 12, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Nigel Dally Maintained (ARQT) at Buy with Decreased Target to $47 on, Apr 12th, 2023
Nigel Dally of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Decreased Target from $50 to $47 on, Apr 12th, 2023.
Nigel has made no other calls on ARQT in the last 4 months.
There are 4 other peers that have a rating on ARQT. Out of the 4 peers that are also analyzing ARQT, 0 agree with Nigel's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Nigel
- Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $61 on, Tuesday, April 11th, 2023
- Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Decreased Target to $45 on, Wednesday, March 29th, 2023
- Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $24 on, Thursday, March 16th, 2023
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023
Contributing Sources